Clinical trials
Sexually Transmitted Infections (Not HIV or Hepatitis) clinical trials
Below are recruiting sexually transmitted infections (not hiv or hepatitis) clinical trials, each written for real people, not researchers. We’re tracking 779 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05937178Recruiting
Real-World Study to Optimize Hepatitis B Tablet Treatment
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hefei, AnhuiAges 18–80 - NCT05617859RecruitingPhase 2
Lenvatinib treatment for advanced bone or soft tissue sarcoma
This trial tests lenvatinib to shrink or control advanced bone or soft tissue sarcoma that can’t be safely treated with surgery. You may be eligible if your cancer has measurable spots and you’ve had specific prior drug treatments without a durable response.
Zhengzhou, HenanAges 10–70 - NCT05686785Recruiting
Test how reliable a liver scan is in chronic hepatitis
This study checks whether a “liver stiffness” scan (called transient elastography) gives consistent, dependable results in adults with long-term viral hepatitis. It may help improve how doctors monitor liver changes over time.
Helsingborg, Skåne CountyAges 18 years+ - NCT04446832Recruiting
Vaccine study for people waiting for liver transplant
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
LyonAges 18 years+ - NCT03868722RecruitingPhase 2/Phase 3
Acalabrutinib plus venetoclax for high-risk CLL with infection risk
This study tests whether acalabrutinib plus venetoclax can control newly diagnosed chronic lymphocytic leukemia (CLL) in people who are at higher risk of infections or who likely need treatment soon. It aims to see if this combination can improve disease control while keeping patients safe.
CopenhagenAges 18 years+ - NCT05557448RecruitingPhase 2
N-Acetylcysteine treatment for serious acetaminophen overdose
This Phase 2 trial studies whether TYNADOTE® can treat people who have taken a harmful acetaminophen (Tylenol) overdose while checking safety. It may be considered if your overdose is high enough to put you at risk for liver injury and you can follow the treatment and follow-up visits.
Taipei, Beitou DistrictAges 20 years+ - NCT06201065RecruitingPhase 3
Targeted therapy and immunotherapy for advanced liver cancer
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Guangzhou, GuangdongAges 18–75 - NCT06210178Recruiting
New way to measure liver pressure without needles
This study tests a new, non-invasive method (using an MRI) to estimate pressure in the veins of the liver. If successful, it could replace the need for a catheter procedure for patients being evaluated for a liver transplant.
Leiden, South HollandAges 18–75 - NCT06244225RecruitingPhase 2
Triple therapy for advanced liver cancer (HAIC + sintilimab + donafenib)
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
Wuhan, HubeiAges 18 years+ - NCT07867587Enrolling by invitation
Radiological treatment for blocked portal vein in children
This study tests a minimally invasive procedure to restore blood flow in children with a blocked portal vein (the major vein carrying blood from the intestines to the liver). It aims to reduce complications like bleeding from enlarged veins in the stomach or esophagus, an enlarged spleen, or fluid buildup in the belly.
CairoAges 2–17 - NCT04231565Recruiting
Testing antiviral medicines for hepatitis B with normal liver blood tests
This trial studies how well nucleoside (nucleoside-acid) type antiviral medicines control hepatitis B in people whose liver enzyme test (ALT) is currently normal. It may help those with active hepatitis B but no major liver inflammation on recent bloodwork.
Guangzhou, GuangdongAges 18–65 - NCT03811236Recruiting
Test cold exposure to activate body fat and reduce liver fat
This study tests whether controlled cold exposure can activate “brown fat” and affect liver fat buildup. It may help people with excess liver fat, measured on imaging, but it has several health and medication exclusions.
ViennaAges 18–50 - NCT06180590Recruiting
Vosevi for hepatitis C patients who didn't get better with past antiviral treatment
This trial tests if Vosevi (a combination of three antiviral drugs) can clear the hepatitis C virus in people who have already tried standard antiviral treatment but still have the virus. It also compares this to another treatment option.
Guangzhou, GuangdongAges 20–70 - NCT06323681Recruiting
Lower-dose interferon for chronic hepatitis B patients who've tried it before
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06398028RecruitingPhase 4
ICG dye before minimally invasive liver surgery
This study tests whether giving a special dye (ICG) before minimally invasive liver surgery helps surgeons see tumors more clearly compared to using ultrasound alone. It’s for people who are already scheduled for keyhole liver surgery.
BarcelonaAges 18 years+ - NCT06406634RecruitingPhase 2
Cadonilimab, Lenvatinib, and HAIC for Unresectable Liver Cancer
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
Changsha, HunanAges 18–75 - NCT07847359RecruitingPhase 2
Freezing and drug combination for melanoma that has spread to the liver
This trial tests a combination of treatments for melanoma that has spread to the liver after standard treatment. It uses freezing (cryoablation), a targeted drug (lenvatinib), chemotherapy (dacarbazine), and two immunotherapy drugs to try to shrink liver tumors and control the cancer. The goal is to see if this combined approach is safe and effective for patients whose cancer has not responded to prior therapy.
Guangzhou, GuangdongAges 18–75 - NCT06449833RecruitingPhase 4
Henagliflozin for liver fat in diabetes and fatty liver
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
Guangzhou, GuangdongAges 18–75 - NCT07841574RecruitingPhase 2
Combination treatment for bile duct cancer in the liver
This trial tests a new combination of treatments for intrahepatic cholangiocarcinoma (a bile duct cancer in the liver) that cannot be surgically removed. It combines chemo directly into the liver with two drugs that boost the immune system and block blood vessel growth, hoping to shrink the tumor and help you live longer.
Guangzhou, GuangdongAges 18–75 - NCT07833592Recruiting
Liver-targeted treatment for genetic leptin-related obesity
This study is for people with a rare genetic condition that causes severe obesity and high appetite, called leptin receptor deficiency or related leptin problems. The trial tests a new approach that targets the liver to help with weight control, and it aims to see if this can improve their condition.
Novara, ItalyAges Any age - NCT03949231RecruitingPhase 3
Infusion immunotherapy through the liver artery for liver cancer
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Guanzhou, GuangdongAges 18–80 - NCT07818629RecruitingPhase 1
Testing a vaccine to prevent stomach flu in healthy adults
This trial tests an investigational vaccine called INT101 to see if it can prevent norovirus, a common cause of stomach flu (vomiting and diarrhea). It is given to healthy adults to check its safety and how well it works before moving to larger studies.
SeoulAges 19–48 - NCT07824622RecruitingPhase 1
Early safety study of an investigational drug in healthy adults
This study tests an investigational drug called AZD0543 to see if it is safe and how the body processes it. It is for healthy adults, not for treating a specific disease.
Los Alamitos, CaliforniaAges 18–55 - NCT06492408RecruitingPhase 2
Immunotherapy before surgery for liver cancer
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Guanzhou, GuangdongAges 18–75
Hear when a new Sexually Transmitted Infections (Not HIV or Hepatitis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sexually transmitted infections (not hiv or hepatitis)?
- Yes. Clin2 currently lists 779 recruiting sexually transmitted infections (not hiv or hepatitis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sexually transmitted infections (not hiv or hepatitis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sexually transmitted infections (not hiv or hepatitis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.